Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL480246 | 0.74 | ALDH1A1 (0.38) | ALDH1A1POLBCASP3MAPTSMN1; SMN2 | |
| SCHEMBL540514 | 0.68 | CASP3 (0.62) | ALDH1A1CASP3SMN1; SMN2KMT2AHTT | |
| SCHEMBL29802648 | 0.68 | CASP3 (0.62) | ALDH1A1CASP3SMN1; SMN2KMT2AHTT | |
| SCHEMBL10743632 | 0.68 | ALDH1A1 (0.55) | ALDH1A1POLBCASP3MAPTSMN1; SMN2 | |
| SCHEMBL11364469 | 0.68 | ALDH1A1 (0.55) | ALDH1A1POLBCASP3MAPTSMN1; SMN2 | |
| SCHEMBL6701969 | 0.67 | ALDH1A1 (0.48) | ALDH1A1POLBCASP3MAPTSMN1; SMN2 | |
| SCHEMBL10179103 | 0.67 | ALDH1A1 (0.51) | ALDH1A1POLBMAPTSMN1; SMN2 | |
| SCHEMBL19695649 | 0.67 | ALDH1A1 (0.48) | ALDH1A1POLBCASP3MAPTSMN1; SMN2 | |
| SCHEMBL10179102 | 0.65 | ALDH1A1 (0.49) | ALDH1A1POLBCASP3MAPTSMN1; SMN2 | |
| SCHEMBL31751926 | 0.64 | ALDH1A1 (0.65) | ALDH1A1POLBCASP3KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258851-A1 | DIARYL SUBSTITUTED ALKANES | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| US-20090258851-A1 | DIARYL SUBSTITUTED ALKANES | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258851-A1 | DIARYL SUBSTITUTED ALKANES | ALOX5, ALOX15, LTB4R2 | ALDH1A1 328/4885POLB 3760/4885CASP3 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.